- Home
- DPG vs LAB Comparison
DPG vs LAB Comparison
Compare DPG & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DPG | LAB |
|---|---|---|
| Founded | N/A | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 535.3M | 488.4M |
| IPO Year | 2011 | 2008 |
Fundamental Metrics
Financial Performance| Metric | DPG | LAB |
|---|---|---|
| Price | $14.21 | $0.93 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.35 |
| AVG Volume (30 Days) | 107.9K | ★ 2.3M |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 44.68 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $101,937,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.63 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.45 | $0.92 |
| 52 Week High | $14.96 | $1.72 |
Technical Indicators
Market Signals| Indicator | DPG | LAB |
|---|---|---|
| Relative Strength Index (RSI) | 50.74 | 23.71 |
| Support Level | $12.37 | N/A |
| Resistance Level | $14.68 | $1.41 |
| Average True Range (ATR) | 0.21 | 0.07 |
| MACD | -0.10 | -0.01 |
| Stochastic Oscillator | 18.18 | 2.75 |
Price Performance
Historical ComparisonAbout DPG Duff & Phelps Utility and Infrastructure Fund Inc.
Duff & Phelps Utility & Infrastructure Fund Inc. is an investment fund, and its objective is to seek total return, derived mainly from a high level of current income, with an emphasis on providing tax-advantaged dividend income and growth in current income, and secondarily from capital appreciation.
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.